gross profit bridgeinconsistent2025-06-30
Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.
Revenue
$29.10M
Fiscal year ended 2026-06-30Operating income
-$14.36M
Fiscal year ended 2026-06-30Free cash flow
-$16.99M
Fiscal year ended 2026-06-30GYRE THERAPEUTICS, INC. (GYRE) reported revenue of $29.10M and net income of -$14.27M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from GYRE THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.10M | $22.52M | $37.20M | $30.56M | $29.73M | $22.06M | $27.87M | $25.49M | $25.22M | $27.17M |
| Cost of revenue | $2.21M | $1.23M | $1.74M | $1.63M | Unavailable | $894.00K | $1.18M | $958.00K | $770.00K | $979.00K |
| Gross profit | $26.90M | $21.29M | $35.45M | $28.94M | Unavailable | $21.16M | $26.70M | $24.53M | $24.46M | $26.19M |
| Operating income | -$14.36M | -$9.36M | $118.00K | $6.92M | -$2.24M | $2.27M | $665.00K | $4.23M | $3.19M | $8.07M |
| Net income | -$14.27M | -$18.58M | -$1.32M | $5.94M | -$2.24M | $4.94M | $598.00K | $2.86M | $4.54M | $9.94M |
| Research & development | Unavailable | $6.74M | $4.82M | $2.36M | $8.35M | $3.10M | $3.71M | $2.78M | $3.36M | $2.18M |
| Weighted-average diluted shares | shares 100.64M | shares 91.34M | Unavailable | shares 103.97M | shares 89.20M | shares 101.97M | Unavailable | shares 102.64M | shares 102.21M | shares 102.59M |
| Pretax income | -$14.43M | -$9.24M | -$66.00K | $7.63M | -$1.58M | $4.64M | $772.00K | $3.93M | $6.04M | $12.48M |
| Income tax expense | -$164.00K | $621.00K | $1.30M | $1.69M | $662.00K | $901.00K | $203.00K | $1.07M | $1.50M | $2.55M |
| Diluted EPS | $-0.12 | $-0.10 | Unavailable | $0.03 | $-0.03 | $0.00 | Unavailable | $0.01 | $0.01 | $0.03 |
| Selling, general & administrative | $7.86M | $21.36M | $30.52M | $19.65M | $7.28M | $15.80M | $22.32M | $17.52M | $17.84M | $15.94M |
| General & administrative | $7.87M | $7.22M | $6.70M | $4.32M | $7.28M | $4.96M | $5.46M | $3.82M | $3.42M | $3.40M |
| Selling & marketing | $13.75M | $14.14M | $23.82M | $15.33M | $15.20M | $10.84M | $16.86M | $13.70M | $14.41M | $12.54M |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $43.29M | $37.50M | $49.19M | $40.40M | $36.49M | $15.04M | $11.81M | $15.87M | $16.10M | $29.78M |
| Total assets | $199.26M | $162.02M | $219.76M | $159.38M | $152.65M | $129.79M | $125.41M | $125.24M | $120.93M | $122.01M |
| Current assets | $122.07M | $91.73M | $149.36M | $98.58M | $91.28M | $68.45M | $64.79M | $54.81M | $53.52M | $62.72M |
| Total liabilities | $34.34M | $25.03M | $31.40M | $21.97M | $23.20M | $25.49M | $27.00M | $26.77M | $27.58M | $33.24M |
| Current liabilities | $28.66M | $19.79M | $23.78M | $15.91M | $16.92M | $18.99M | $19.52M | $14.72M | $15.57M | $19.49M |
| Total equity incl. NCI | $142.49M | $43.08M | $59.54M | $137.42M | $59.61M | $40.68M | $35.79M | $98.47M | $93.35M | $88.77M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $11.43M | $11.35M | $10.17M | Unavailable | $8.86M | $7.88M | $6.34M | $6.38M | $5.64M | $4.94M |
| Accounts receivable | $27.76M | $22.76M | $31.08M | $25.88M | $24.63M | $20.15M | $19.59M | Unavailable | Unavailable | Unavailable |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $1.24M | $265.00K | $1.34M | $556.00K | $71.00K | $122.00K | $108.00K | $303.00K | $271.00K | $330.00K |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.73M | $3.18M | -$5.62M | $14.24M | -$7.47M | -$129.00K | -$2.76M | $1.73M | -$5.49M | $2.88M |
| Capital expenditures | $262.00K | $178.00K | $144.00K | $589.00K | $335.00K | $122.00K | -$65.00K | $693.00K | $1.46M | $231.00K |
| Investing cash flow | $9.76M | -$3.06M | $1.85M | -$5.64M | $1.35M | $1.97M | -$2.00M | -$2.39M | -$8.27M | -$7.22M |
| Financing cash flow | -$8.00K | $21.00K | $318.00K | $2.47M | $20.24M | $1.34M | $964.00K | $324.00K | $156.00K | $658.00K |
| Net change in cash | -$6.34M | $431.00K | -$3.33M | $11.27M | $14.08M | $3.23M | -$4.05M | -$231.00K | -$13.69M | -$3.72M |
| Stock-based compensation | $2.08M | $2.58M | $4.60M | $617.00K | $1.44M | $507.00K | $567.00K | $237.00K | $16.00K | $11.00K |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $1.48M | $672.00K | $656.00K | $281.00K | $1.01M | $535.00K | $461.00K | $445.00K | $228.00K | $415.00K |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | -$16.99M | $3.00M | -$5.77M | $13.65M | -$7.81M | -$251.00K | Unavailable | $1.03M | -$6.95M | $2.65M |
| Gross margin | 92.4% | 94.6% | 95.3% | 94.7% | Unavailable | Unavailable | Unavailable | 96.2% | 96.9% | 96.4% |
| Operating margin | -49.3% | -41.5% | 0.3% | 22.7% | -7.5% | 10.3% | 2.4% | 16.6% | 12.7% | 29.7% |
| FCF margin | -58.4% | 13.3% | -15.5% | 44.7% | -26.3% | -1.1% | Unavailable | 4.1% | -27.5% | 9.8% |
| SBC / revenue | 7.1% | 11.5% | 12.4% | 2.0% | 4.8% | 2.3% | 2.0% | 0.9% | 0.1% | 0.0% |
| Current ratio | 4.26x | 4.64x | 6.28x | 6.19x | 5.40x | 3.60x | 3.32x | 3.72x | 3.44x | 3.22x |
| Revenue YoY growth | -2.1% | 2.1% | 33.4% | 19.9% | 17.9% | -18.8% | 2.7% | -20.5% | -14.0% | 9.0% |
| Net margin | -49.0% | Unavailable | -3.5% | 19.4% | -7.5% | Unavailable | 2.1% | 11.2% | Unavailable | Unavailable |
| R&D / revenue | Unavailable | 29.9% | 12.9% | 7.7% | 28.1% | 14.0% | 13.3% | 10.9% | 13.3% | 8.0% |
| CapEx / revenue | 0.9% | 0.8% | 0.4% | 1.9% | 1.1% | 0.6% | -0.2% | 2.7% | 5.8% | 0.9% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | 22.2% | Unavailable | 19.4% | 26.3% | 27.3% | 24.8% | 20.4% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GYRE in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-13View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-09View SEC filing
Reconciliation checks needing review
16 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2026-06-30
Difference 22430000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2026-03-31
Difference 93900000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2025-12-31
Difference 128814000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2025-06-30
Difference 69833000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2025-03-31
Difference 63627000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2024-12-31
Difference 62612000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
cash flow reconciliationreview2023-12-31
Operating, investing and financing flows differ from the reported change in cash by 12740000, beyond tolerance 1000000.
balance equationreview2023-12-31
Difference 64525000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
cash flow reconciliationreview2023-09-30
Operating, investing and financing flows differ from the reported change in cash by 1478000, beyond tolerance 1000000.
balance equationreview2023-09-30
Difference 81801000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2023-06-30
Difference 72473000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.